Nucla Competitors

Kaiser Permanente's Division of Research (DOR) is one of the nation’s largest research facilities outside of a government or university setting. Our studies cover a wide range of clinical topics, including cardiovascular disease, cancer, diabetes, substance abuse, mental health, maternal and child health, and women’s health. Our research addresses broad issues, including the role of genes and the environment in health, the influence of behavior on disease prevention and chronic illness management, drug safety, health care policy, health services delivery, and disparities. The Division is currently home to 75 research scientists and staff scientists, 17 research fellows, and more than 674 employees. The DOR also has 46 adjunct investigators from within Kaiser Permanente Northern California (KPNC) and other academic institutions. DOR’s scientists are involved in 612 ongoing research projects and the KPNC Clinical Trials Program supports and guides 326 active clinical trials following 3,917 members. Since 2000, DOR researchers have published more than 8,100 peer-reviewed articles, and across all KPNC researchers there were more than 1,000 papers published in 2025 alone.

Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion. Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories. Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients. Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions. The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals. More information is available at www.questdiagnostics.com. Language Assistance / Non-Discrimination Notice Asistencia de Idiomas / Aviso de no Discriminación 語言協助 / 不歧視通知 www.QuestDiagnostics.com/home/nondiscrimination

Clear and confident health care decisions begin with questions. At Labcorp, we’re constantly in pursuit of answers. As a global leader of innovative and comprehensive laboratory services, we help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Our more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about Labcorp (NYSE: LH) at www.labcorp.com.